DrugPatentWatch Database Preview
Drugs in Development Information for Momelotinib
» See Plans and Pricing
What is the drug development status for Momelotinib?
Momelotinib is an investigational drug.
There have been 14 clinical trials for Momelotinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2014.
The most common disease conditions in clinical trials are Thrombocytosis, Thrombocythemia, Essential, and Primary Myelofibrosis. The leading clinical trial sponsors are Gilead Sciences, Sierra Oncology, Inc., and Fred Hutchinson Cancer Research Center.
There are three hundred and thirty-four US patents protecting this investigational drug and two international patents.
Summary for Momelotinib
| US Patents | 334 |
| International Patents | 2,668 |
| US Patent Applications | 813 |
| WIPO Patent Applications | 689 |
| Japanese Patent Applications | 247 |
| Clinical Trial Progress | Phase 2 (2014-06-01) |
| Vendors | 84 |
Recent Clinical Trials for Momelotinib
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 3 Study Comparing the Activity of Momelotinib in Symptomatic and Anemic Myelofibrosis Patients Versus Danazol | Sierra Oncology, Inc. | Phase 3 |
| Extended Access of Momelotinib in Adults With Myelofibrosis | Gilead Sciences | Phase 2 |
| Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | Gilead Sciences | Phase 2 |
Clinical Trial Summary for Momelotinib
Top disease conditions for Momelotinib
Top clinical trial sponsors for Momelotinib
US Patents for Momelotinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Momelotinib | Get Started for $10 | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | Get Started for $10 |
| Momelotinib | Get Started for $10 | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Pharmacyclics LLC (Sunnyvale, CA) | Get Started for $10 |
| Momelotinib | Get Started for $10 | Bicyclic bromodomain inhibitors | Zenith Epigenetics Ltd. (Calgary, AB, CA) | Get Started for $10 |
| Momelotinib | Get Started for $10 | Methods for the treatment of HER2 amplified cancer | Pharmacyclics LLC (Sunnyvale, CA) | Get Started for $10 |
| Momelotinib | Get Started for $10 | Benzimidazole derivatives as bromodomain inhibitors | Gilead Sciences, Inc. (Foster City, CA) | Get Started for $10 |
| Momelotinib | Get Started for $10 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (Atlanta, GA) | Get Started for $10 |
| Momelotinib | Get Started for $10 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (Cambridge, MA) | Get Started for $10 |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Momelotinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Momelotinib | Australia | AU2015244171 | 2034-04-11 | Get Started for $10 |
| Momelotinib | Australia | AU2015244179 | 2034-04-11 | Get Started for $10 |
| Momelotinib | Canada | CA2945128 | 2034-04-11 | Get Started for $10 |
| Momelotinib | Canada | CA2945129 | 2034-04-11 | Get Started for $10 |
| Momelotinib | China | CN106414451 | 2034-04-11 | Get Started for $10 |
| Momelotinib | China | CN106459063 | 2034-04-11 | Get Started for $10 |
| Momelotinib | European Patent Office | EP3129377 | 2034-04-11 | Get Started for $10 |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
